Last reviewed · How we verify
Rivaroxaban (BAY59-7939)
Rivaroxaban (BAY59-7939) is a Factor Xa inhibitor Small molecule drug developed by Bayer. It is currently in Phase 3 development for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.
Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade.
Rivaroxaban is a direct Factor Xa inhibitor that prevents the coagulation cascade. Used for Deep vein thrombosis, Pulmonary embolism, Atrial fibrillation for stroke prevention.
At a glance
| Generic name | Rivaroxaban (BAY59-7939) |
|---|---|
| Sponsor | Bayer |
| Drug class | Factor Xa inhibitor |
| Target | Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by selectively inhibiting Factor Xa, a key enzyme in the coagulation cascade, thereby preventing the formation of blood clots. This mechanism of action is specific to the coagulation pathway and does not affect other physiological processes.
Approved indications
- Deep vein thrombosis
- Pulmonary embolism
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Gastrointestinal bleeding
- Hemorrhage
- Thrombocytopenia
- Anemia
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
- Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
- Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
- Study to Gain Information on the Drug Xarelto for the Prevention of Brain Attack and Blockage of an Artery in the Non-central Nervous System Due to Irregular Heartbeat in Taiwanese Patients Suffering From Decreased Renal Function
- A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
- Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivaroxaban (BAY59-7939) CI brief — competitive landscape report
- Rivaroxaban (BAY59-7939) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Rivaroxaban (BAY59-7939)
What is Rivaroxaban (BAY59-7939)?
How does Rivaroxaban (BAY59-7939) work?
What is Rivaroxaban (BAY59-7939) used for?
Who makes Rivaroxaban (BAY59-7939)?
What drug class is Rivaroxaban (BAY59-7939) in?
What development phase is Rivaroxaban (BAY59-7939) in?
What are the side effects of Rivaroxaban (BAY59-7939)?
What does Rivaroxaban (BAY59-7939) target?
Related
- Drug class: All Factor Xa inhibitor drugs
- Target: All drugs targeting Factor Xa
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Deep vein thrombosis
- Indication: Drugs for Pulmonary embolism
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Compare: Rivaroxaban (BAY59-7939) vs similar drugs
- Pricing: Rivaroxaban (BAY59-7939) cost, discount & access